Navigation Links
Oramed Announces Dual-Listing on Tel Aviv Stock Exchange
Date:7/5/2017

JERUSALEM, July 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received approval from the Israel Securities Authority to dual-list its common stock on the Tel Aviv Stock Exchange (TASE). Oramed common stock will commence trading on the TASE on July 12, 2017 under the ticker ORMP.  Based on the current market capitalization of the Company, it is expected that Oramed will be included in the TA SME-60 index.

Oramed common stock will continue to be listed and traded on the NASDAQ Capital Markets and the Company will continue to comply with the regulations of the U.S. Securities and Exchange Commission. Per the TASE's listing requirements and Israel's Dual Listing Law, U.S. listed companies may dual-list on the TASE without any additional regulatory reporting or requirements.

"We believe dual-listing on the TASE will provide many benefits to our Company and our shareholders. An expanded investor pool including Israel's largest institutional investors, eligibility for being included in Israel's index funds, and expanded trading days and hours to serve global investors especially those in Europe and Asia, are all factors that we believe will contribute to superior trading, liquidity and valuation for Oramed stock," stated Oramed CEO Nadav Kidron.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's POD™ technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).  The Company completed multiple Phase II clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit www.oramed.com

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss the expected inclusion of our stock in the TA SME-60 index, or revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact
Oramed Pharmaceuticals
Josh Hexter
Office: +972-2-566-0001 ext. 2
US: 1-718-831-2512 ext. 2
Email:  josh@oramed.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oramed-announces-dual-listing-on-tel-aviv-stock-exchange-300483339.html


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed Granted Canadian Patent for GLP-1 Analog Capsule
2. Oramed to Present at the American Diabetes Association 76th Scientific Sessions
3. Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study
4. Oramed to Present at Oppenheimer Annual Israeli Conference
5. Oramed Patent Being Granted in China for Oral Administration of Proteins
6. Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
7. Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent
8. Oramed Completes Phase IIb Oral Insulin Study
9. Oramed Patent Granted in India for Oral Administration of Proteins
10. Oramed Pharmaceuticals Shareholder Letter
11. Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly ... announced actions to streamline operations to more efficiently ... improve its cost structure. Global workforce reductions, including ... are expected to impact approximately 3,500 positions. ... company expects annualized savings of approximately $500 million ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... ... health supplement developed by a neurosurgeon, has received a big bump in ... Daily Brain Booster is currently available on the Wal-Mart Stores-owned Jet.com, StackedNutrtion.com, ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... board-certified veterinary oncologist, has agreed to serve as strategic adviser to the ... Tripp is founder of the Bridge Animal Referral Center (BARC) in Edmonds, ...
(Date:9/19/2017)... , ... September 19, 2017 , ... First Choice ... States, named Dr. Howard Ng, as the new Medical Director of its Pflugerville- FM ... new facility Medical Director of our Pflugerville- FM 685 location,” said Dr. Stephen Van ...
(Date:9/19/2017)... ... , ... Ron Norman, CEO of Team Decades, http://www.teamdecades.com , stressed to ... than generic impression in the job market if one is looking for career expansion. ... that the first impression they give off is not a good one," says Norman, ...
(Date:9/19/2017)... ... 19, 2017 , ... When it comes to household safety, there are few ... how to keep babies and toddlers safe, and there's no better time for companies ... Time to Check Labels, Brands that sell all kinds of common consumer products should ...
Breaking Medicine News(10 mins):